All lobbying filings

FORBES-TATE

FORBES-TATE filed a Q1 report for SANOFI U.S. on April 19, 2026, reporting $50,000 in lobbying income.

Lobbying for SANOFI U.S. · Multinational Pharmaceutical Company

All filings by FORBES-TATE · Everything SANOFI U.S. has reported

Filing · LD-2 quarterly report Q1 report

Reporting period

1st Quarter 2026

Jan 1 - Mar 31 · Posted Apr 19, 2026

Income

$50,000

What the client paid this registrant for the period.

Client based in

District of Columbia

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 3

Health Issues

Issues related to prescription drug pricing; Issues related to Section 340B of the Public Health Service Act (P.L. 78-410); Drug pricing issues related to the implementation of the Inflation Reduction Act of 2022 (P.L. 117-169); Issues related to flu and RSV vaccines.

Medicare/Medicaid

Issues related to prescription drug pricing, including the implementation of the Inflation Reduction Act of 2022 (P.L. 117-169); Issues related to Section 340B of the Public Health Service Act (P.L. 78-410); Issues related to pharmacy benefit managers.

Taxation/Internal Revenue Code

Issues related to orphan drug tax credit; Issues related to the excise tax for the Vaccine Injury Compensation Fund.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.